SFEBES2021 Poster Presentations Reproductive Endocrinology (31 abstracts)
Effect of pharmacological interventions on lipid profiles and C-reactive protein in polycystic ovary syndrome: a systematic review and meta-analysis
Mohammed Abdalla 1 , Najeeb Shah 1 , Harshal Deshmukh 1 , Amirhossein Sahebkar 2,3 , Linda Östlundh 4 , Rami H. Al-Rifai 5 , Stephen L Atkin 6 & Thozhukat Sathyapalan 1
1Academic Diabetes, Endocrinology and Metabolism, The University of Hull, Hull York Medical School (HYMS), Hull, United Kingdom; 2Biotechnology Research Centre, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 3Applied Biomedical Research Centre, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran; 4College of Medicine and Health Sciences, The National Medical Library, United Arab Emirates University, Al Ain, UAE; 5College of Medicine and Health Sciences, Institute of Public Health, United Arab Emirates University, Al Ain, UAE; 6School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Adliya, Bahrain
Context: Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of reproductive age. It is associated with dyslipidaemia and elevated plasma C-reactive protein (CRP), which increase the risks of cardiovascular disease (CVD).
Objective: To review the existing evidence on the effects of different pharmacological interventions on lipid profiles of women with PCOS.
Data sources: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane Library, and Web of Science in April 2020 and updated the results in March 2021.
Study selection: The study included randomised controlled trials (RCTs) and follows the 2020 Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA).
Data extraction: Two independent researchers extracted data and assessed for risk of bias using the Cochrane risk of bias tool. Covidence systematic review software was used for blinded screening and study selection.
Data synthesis: In 29 randomised controlled trials (RCTs), there were significant reductions in triglycerides with atorvastatin vs placebo (MD: -0.21 mmol/l ; 95% CI: -0.39, -0.03, I² = 0%, moderate grade evidence). Significant reductions were seen for LDL-C with metformin vs placebo (SMD:-0.41;95%CI:-0.85, 0.02,I²= 59%, low grade evidence). Significant reductions were seen for total cholesterol with saxagliptin vs metformin (MD:-0.15 mmol/l ; 95% CI: -0.23, -0.08, I² = 0%, very low grade evidence). HDL-C was significantly reduced for saxagliptin vs metformin (MD: -0.11 mmol/l ; 95%CI: -0.15, -0.06, I² = 7%, very low grade evidence). Significant reductions in C-reactive protein (CRP) were seen for atorvastatin vs placebo (MD:-1.51 mmol/l ;95%CI:-3.26-0.24, I²=75%, very low-grade evidence).
Conclusion: There were significant reductions in the lipid parameters when metformin, atorvastatin, rosiglitazone and pioglitazone were compared with placebo or other agents. There was also a significant reduction of CRP with atorvastatin.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more